The Schizophrenia drugs in development market research report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Schizophrenia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Schizophrenia and features dormant and discontinued products.

GlobalData tracks 172 drugs in development for Schizophrenia by 123 companies/universities/institutes. The top development phase for Schizophrenia is preclinical with 61 drugs in that stage. The Schizophrenia pipeline has 163 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Schizophrenia pipeline products market are: Omeros, Cerevel Therapeutics and AbbVie.

The key targets in the Schizophrenia pipeline products market include D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2), 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A), and 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A).

The key mechanisms of action in the Schizophrenia pipeline product include 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Antagonist with 32 drugs in Pre-Registration. The Schizophrenia pipeline products include nine routes of administration with the top ROA being Oral and five key molecule types in the Schizophrenia pipeline products market including Small Molecule, and Synthetic Peptide.

Schizophrenia overview

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications.

For a complete picture of Schizophrenia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.